The continued progress in understanding and deciphering the critical role of the DNA damage response might help us stratify cancer patients in the future and personalize their therapies.
September 2015
Due to the unique characteristics of adolescents and young adults, there is a growing effort to address their oncology needs.
The FDA closed out summer 2015 by taking action on several oncology drug applications, approving new indications and granting several priority reviews.
Advanced SCCS continues to be a treatment challenge given the aggressive behavior of a subset of cases and the absence of randomized clinical trials to provide guidelines for therapy.
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5